Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

Hair regeneration and follicle cloning are considered far from being feasible, with current treatments like finasteride, minoxidil, and hair transplants expected to remain dominant for the next 15-20 years. Some are hopeful that AI advancements might accelerate progress, but many remain skeptical about significant breakthroughs in the near future.

A 21-year-old is concerned about whether their hairline is a normal mature hairline or indicates male pattern baldness, despite no family history of baldness. They plan to provide clearer pictures for better assessment.

Dutasteride can cause hair shedding even with suppressed testosterone levels due to previous damage from DHT. Hair shedding is often a sign of damaged hair being replaced by healthier growth.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

Hair loss is humorously blamed on ancient selection preferences, with discussions on genetics and societal norms. Treatments like finasteride are mentioned as modern solutions.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.

To increase hair density appearance, options include using hair fibers, volume powders, scalp micropigmentation, and a combination of sea salt and holding sprays. Tape-in extensions and clip-in fringes are also considered, but cost and maintenance are concerns.

Common misconceptions about hair loss treatments include the belief that lower doses of finasteride are as effective as higher doses, and that ketoconazole is effective for androgenetic alopecia without scalp issues. Additionally, minoxidil's effects can be seen sooner than commonly thought, and topical dutasteride is effective.

The user is using topical minoxidil, topical finasteride, microneedling, and Nizoral shampoo for hair regrowth. Other users suggest the appearance of regrowth might be due to brushing hair differently.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Diffuse thinning is worse than a receding hairline as it affects the entire scalp, complicating styling and hair transplants. Treatments like finasteride, minoxidil, dutasteride, and RU58841 are mentioned, with some users noting improved hair density.

The conversation discusses hair regrowth progress using Minoxidil, finasteride, and RU58841. It highlights the transformation of vellus hairs into terminal hairs in a Norwood 6 frontal area.

The user experienced reduced effectiveness of minoxidil after consistent use, despite using dutasteride to maintain hair. They are considering alternatives like microneedling and exploring options like hair transplants due to dissatisfaction with current hair density.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

Pregnancy can temporarily reverse hair loss in women, but attempts to mimic pregnancy hormones with treatments like contraceptive pills, spironolactone, estradiol, progesterone, finasteride, and minoxidil have been ineffective. The discussion highlights the need for research into the hormonal mechanisms of pregnancy that affect hair regrowth.

The user experienced temporary peach fuzz growth using a product with procapil and later tried minoxidil and finasteride without significant results. Their boyfriend has used minoxidil and finasteride consistently for over five years with sparse hair improvement.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

Finasteride and oral minoxidil effectively maintain a youthful appearance and full head of hair, despite genetic predispositions to balding. The discussion also considers the impact of DHT blockers on masculinity and aging, with lifestyle choices like sunscreen use and a vegetarian diet mentioned.

A user experienced significant hair shedding and thinning 10 months post-hair transplant despite using minoxidil and topical finasteride. They are considering switching to oral finasteride or dutasteride and are also dealing with scalp conditions like seborrheic dermatitis.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.

AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

A user is considering switching from oral minoxidil to a combination of 5% topical minoxidil and tretinoin to reduce hypertrichosis. They hope this combination will be effective without causing excessive body hair growth.

The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.

A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.